Dr Michael Pishvaian's guest appearances

Dr Michael Pishvaian

Gastrointestinal Cancer Update

Oncology Today with Dr Neil Love

Stephen Liu

David Quinn

Philip A Philip

Ezra Cohen

Tom Lynch

Eric Klein

John Heymach

Leora Horn

Jeffrey Bradley

Benjamin Levy

Kathleen Moore

Kelly Goodwin

Jonathon Cohen

Peter Hillmen

Noopur Raje

OwlTail

Michael Pishvaian

Dr Michael Pishvaian from the Johns Hopkins University School of Medicine in Washington, DC, discusses recent therapeutic advances in pancreatic cancer. CME information and select publications here.

Dr Michael Pishvaian from the Johns Hopkins University School of Medicine in Washington, DC, discusses recent therapeutic advances in pancreatic cancer. CME information and select publications <a href="http://www.researchtopractice.com/OncologyTodayPancreasPARP21" rel="nofollow" target="_blank">here</a>.

PARP Inhibition in Pancreatic Cancer with Dr Michael Pishvaian

Is it worthwhile to treat pancreatic cancer? Dr Michael Pishvaian from Johns Hopkins University discusses the use of the PARP inhibitor olaparib and other new developments in the disease. Additional Resources   Golan T et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381:317-27. Full text Burris HA 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 1997;15(6):2403-13. Abstract Conroy T et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25. Correspondence Von Hoff DD et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703. Full text Doleh Y et al. Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis. Cancer Med 2020;9:3463-76. Full text Mavros MN et al. Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: A population-based analysis. CMAJ 2019;191(21):E574-80. Full text Lowery MA et al. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. JNCI 2018;110(10):1067-74. Full text O’Reilly EM et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol 2020;38(13):1378-88. Full text

Is it worthwhile to treat pancreatic cancer? Dr Michael Pishvaian from Johns Hopkins University discusses the use of the PARP inhibitor olaparib and other new developments in the disease. Additional Resources <ul> <li> Golan T et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381:317-27. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1903387?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed" rel="nofollow" target="_blank">Full text</a></li> <li>Burris HA 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 1997;15(6):2403-13. <a href="https://ascopubs.org/doi/abs/10.1200/JCO.1997.15.6.2403" rel="nofollow" target="_blank">Abstract</a></li> <li>Conroy T et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25. <a href="https://www.nejm.org/doi/full/10.1056/NEJMc1107627?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed" rel="nofollow" target="_blank">Correspondence</a></li> <li>Von Hoff DD et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703. <a href="https://www.nejm.org/doi/10.1056/NEJMoa1304369?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov" rel="nofollow" target="_blank">Full text</a></li> <li>Doleh Y et al. Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis. Cancer Med 2020;9:3463-76<a href="https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.3011" rel="nofollow" target="_blank">. Full text</a></li> <li>Mavros MN et al. Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: A population-based analysis. CMAJ 2019;191(21):E574-80. <a href="https://www.cmaj.ca/content/191/21/E574.long" rel="nofollow" target="_blank">Full text</a></li> <li>Lowery MA et al. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. JNCI 2018;110(10):1067-74. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186514/" rel="nofollow" target="_blank">Full text</a></li> <li>O’Reilly EM et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol 2020;38(13):1378-88. <a href="https://ascopubs.org/doi/full/10.1200/JCO.19.02931?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed" rel="nofollow" target="_blank">Full text</a></li></ul>

Dr Michael Pishvaian Comments on the Use of PARP Inhibition in the Management of Pancreatic Cancer